CGX1321

A Phase 1 Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Subjects With Advanced Solid Tumors and Phase 1b Study of CGX1321 in Combination With Pembrolizumab in Subjects With Advanced Gastrointestinal Tumors. Click here to learn more.

DISTINGUISH

A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer (DisTinGuish). Click here to learn more.

ZWI-ZW25-201

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer. Click here to learn more.


Learn more about Gastric Tumors >

Our Affiliations

 

 QCCA The Cancer FoundationNCI

We’re Here to Help! Click Below to Get Started

Contact Us Now